CN1039321C - 新的β-氨基-α羟基羧酸的制备方法 - Google Patents

新的β-氨基-α羟基羧酸的制备方法 Download PDF

Info

Publication number
CN1039321C
CN1039321C CN92101909A CN92101909A CN1039321C CN 1039321 C CN1039321 C CN 1039321C CN 92101909 A CN92101909 A CN 92101909A CN 92101909 A CN92101909 A CN 92101909A CN 1039321 C CN1039321 C CN 1039321C
Authority
CN
China
Prior art keywords
group
alkyl
hydroxyl
amino
carbon atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92101909A
Other languages
English (en)
Chinese (zh)
Other versions
CN1064683A (zh
Inventor
矢部裕一郎
樱井满也
东田劝
驹井知明
西垣隆
半田宏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN1064683A publication Critical patent/CN1064683A/zh
Application granted granted Critical
Publication of CN1039321C publication Critical patent/CN1039321C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN92101909A 1991-02-08 1992-02-08 新的β-氨基-α羟基羧酸的制备方法 Expired - Fee Related CN1039321C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17341/91 1991-02-08
JP1734191 1991-02-08

Publications (2)

Publication Number Publication Date
CN1064683A CN1064683A (zh) 1992-09-23
CN1039321C true CN1039321C (zh) 1998-07-29

Family

ID=11941358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN92101909A Expired - Fee Related CN1039321C (zh) 1991-02-08 1992-02-08 新的β-氨基-α羟基羧酸的制备方法

Country Status (12)

Country Link
EP (1) EP0498680A1 (enExample)
KR (1) KR920016417A (enExample)
CN (1) CN1039321C (enExample)
AU (1) AU647239B2 (enExample)
CA (1) CA2060844A1 (enExample)
CS (1) CS35692A3 (enExample)
HU (2) HUT60282A (enExample)
IE (1) IE920414A1 (enExample)
IL (1) IL100899A (enExample)
RU (1) RU2120447C1 (enExample)
TW (1) TW304197B (enExample)
ZA (1) ZA92913B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313094B1 (en) 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
WO1993013066A1 (en) * 1991-12-20 1993-07-08 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
MXPA93002392A (es) 1992-03-11 2005-02-04 Narhex Ltd Derivados amino de hidrocarburos-oxo e hidroxi-substituidos.
US6071895A (en) * 1992-03-11 2000-06-06 Narhex Limited Polar-substituted hydrocarbons
US5888992A (en) * 1992-03-11 1999-03-30 Narhex Limited Polar substituted hydrocarbons
US5679688A (en) * 1992-03-11 1997-10-21 Narhex Limited Quinaldoyl-amine derivatives of oxo-and hydroxy-substituted hydrocarbons
DK0560268T3 (da) * 1992-03-13 1995-06-12 Bio Mega Boehringer Ingelheim Substituerede pipecolinsyrederivater som HIV-proteasehæmmere
DE69322127T2 (de) * 1992-05-13 1999-06-24 Japan Energy Corp., Tokio/Tokyo Verfahren zur Herstellung von Peptidderivaten und ihrer Salze
US5644028A (en) * 1992-05-13 1997-07-01 Japan Energy Corporation Process for producing peptide derivatives and salts therefor
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
FI933472A7 (fi) * 1992-08-07 1994-02-08 Sankyo Co Peptider med foermaoga att inhibera effekten av HIV-proteas, deras framstaellning och terapeutiska anvaendning
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
MX9308016A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
IL110898A0 (en) * 1993-09-10 1994-11-28 Narhex Australia Pty Ltd Polar-substituted hydrocarbons
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
CA2182090A1 (en) * 1994-02-02 1995-08-10 William Joseph Hornback Hiv protease inhibitors and intermediates
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0706794B1 (en) * 1994-10-14 2001-12-12 Japan Energy Corporation Anti-aids pharmaceutical preparations and processes for the production thereof
US6222043B1 (en) 1995-06-30 2001-04-24 Japan Energy Corporation Methods of preparing novel dipeptide compounds or pharmaceutically acceptable salts thereof
US5932550A (en) * 1995-06-30 1999-08-03 Japan Energy Corporation Dipeptide compound or pharmaceutically acceptable salt thereof and medical use thereof
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
CA2249747A1 (en) * 1996-12-27 1998-07-09 Tsutomu Mimoto Novel tripeptide compounds and anti-aids drugs
JP4006058B2 (ja) 1997-03-11 2007-11-14 第一三共株式会社 多臓器不全予防及び/又は治療剤
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ES2274567T3 (es) 1997-03-14 2007-05-16 Daiichi Pharmaceutical Co., Ltd. Utilizacion de tcf-ii para el tratamiento de la perdida de peso corporal, la anemia y la elevacion de tnf causadas por el cancer.
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
WO2002080921A1 (en) * 2001-04-09 2002-10-17 Republic Of Korea Composition for inhibiting hiv activity extracted from paecilomyces sp. (tochu-kaso) j300
US7094909B2 (en) 2001-06-11 2006-08-22 Agouron Pharmaceuticals, Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
US7169932B2 (en) 2001-06-11 2007-01-30 Pfizer Inc. HIV protease inhibitors, compositions containing the same, their pharmaceutical uses, material for their synthesis
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
EP1702916A1 (en) * 2005-03-18 2006-09-20 Santhera Pharmaceuticals (Schweiz) GmbH DPP-IV inhibitors
GB0914574D0 (en) * 2009-08-20 2009-09-30 Givaudan Sa Organic compounds
KR102475443B1 (ko) 2020-11-06 2022-12-08 함상덕 자동 필터 먼지제거장치
AU2022239717A1 (en) 2021-03-15 2023-11-02 Maze Therapeutics, Inc. Inhibitors of glycogen synthase 1 (gys1) and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1182110A (en) * 1980-07-10 1985-02-05 Hamao Umezawa Physiologically active tetrapeptides
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives

Also Published As

Publication number Publication date
ZA92913B (en) 1993-05-06
IL100899A0 (en) 1992-11-15
HUT60282A (en) 1992-08-28
CS35692A3 (en) 1992-09-16
IE920414A1 (en) 1992-08-12
CN1064683A (zh) 1992-09-23
HU9200392D0 (en) 1992-04-28
HU211834A9 (en) 1995-12-28
CA2060844A1 (en) 1992-08-09
AU647239B2 (en) 1994-03-17
AU1081292A (en) 1992-08-13
IL100899A (en) 1997-06-10
RU2120447C1 (ru) 1998-10-20
KR920016417A (ko) 1992-09-24
EP0498680A1 (en) 1992-08-12
TW304197B (enExample) 1997-05-01

Similar Documents

Publication Publication Date Title
CN1039321C (zh) 新的β-氨基-α羟基羧酸的制备方法
CN1253441C (zh) 蛋白酶抑制剂
CN1171870C (zh) 半胱氨酸蛋白酶抑制剂
CN1310905C (zh) 具有抗病毒活性的杂环氮杂己烷衍生物
CN1146575C (zh) 用于治疗与凝血酶有关的疾病的肽基杂环化合物
CN1195737C (zh) Hiv蛋白酶抑制剂,其制备方法和组合物及用途
CN1061339C (zh) 天冬氨酰蛋白酶的新的磺胺抑制剂
CN1054598C (zh) 具有药理活性的肼类衍生物及其制备方法
CN1266118C (zh) 新的δ-氨基-γ-羟基-ω-芳基-链烷酰胺类化合物
CN1795188A (zh) 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
CN1894274A (zh) 丙肝病毒ns3丝氨酸蛋白酶的大环抑制剂
CN1852920A (zh) 丝氨酸蛋白酶抑制剂、特别是hcvns3-ns4a蛋白酶抑制剂
CN1208405A (zh) 逆病毒蛋白酶抑制化合物
CN1341593A (zh) 蛋白酶抑制剂
CN1107144A (zh) 取代的杂环羧酰胺酯,它们的制备及它们作为药物的用途
CN1649864A (zh) 丝氨酸蛋白酶、特别是丙型肝炎病毒ns3-ns4蛋白酶的抑制剂
CN1432022A (zh) 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂
CN87101499A (zh) 正斯塔提尼及正环斯塔提尼多肽的制备方法
CN1094055A (zh) 天冬氨酰蛋白酶的新的抑制剂
CN1039596A (zh) 结合逆转录病毒蛋白酶的肽的制备方法
CN1946718A (zh) 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的具有环p4′s的新型酮酰胺
CN1305993A (zh) 用作氧化氮合成酶抑制剂的环状脒基制剂
CN1599729A (zh) Hiv蛋白酶抑制剂、含有它们的组合物、其药物应用及其合成原料
CN1098409A (zh) α-哌嗪酮及其应用
CN1136556A (zh) 芳香族取代的w-氨基链烷酸酰胺和链烷酸二酰胺

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee